The Top 10 Contract Research Organizations: Positioning, Performance and SWOT Analyses

Transcription

1 Brochure More information from The Top 10 Contract Research Organizations: Positioning, Performance and SWOT Analyses Description: Cost containment and regulatory pressures within the pharma industry are driving R&D outsourcing across the globe. Clinical obstacles to approval have become more significant due to the growing availability of existing generic treatments, and the trend to adopt Health Economics Outcomes Research (HEOR) assessments is increasing the complexity of clinical research. As a result, the scope of the CRO industry is expanding, and the global market is predicted to value $35bn by The Top 10 Contract Research Organizations is a report that examines the competitive landscape of the global CRO industry. The latest key issues and evolving business models in the CRO market are identified and the leading companies in this sector are profiled in detail. For each of the top 10 CRO companies, this report provides a detailed examination of financial performance by business segment and growth strategies in the form of key acquisitions and divestments. The opportunities and threats facing each of these leading players are also assessed. This report also examines the size and growth of the global CRO industry, with analysis of major market drivers and trends in CRO destinations. Key Findings The global CRO industry valued $18bn in 2008, an increase of 14% over The CRO market will grow at an annual rate of 14% over the period. Quintiles leads the global CRO market having accrued a market share of 16.9% in 2007, equivalent to sales of $2.7bn. There are over 1,100 players in the industry, and the top 10 players only accounted for 56.1% of the global market in The fragmented structure of the CRO industry has led to an increase in strategic alliances, acquisitions, jointventures and other partnership deals as companies attempt to expand their service offerings and geographical presence. Covance is the second largest global CRO, having registered revenues of $1.5bn 2007, representing a market share of 9.7%. Covance is building global capabilities, with many clinical trials now being conducted in emerging markets. Biomarkers have the potential to become an integral part of clinical research, after the FDA recommended their usage throughout clinical trials to demonstrate desired clinical activity and safety. Use this report to... - Compare the performances of the top 10 CRO companies across key business segments with this report s analysis of Quintiles, Covance, Pharmal Product Development, Charles River Labs, ICON, Parexel, MDS, Kendle, PharmaNet Development and PRA International - Identify the market dynamics of the global CRO industry over the period, discover which emerging markets are becoming the CRO destinations of the future and understand the latest industrial trends across the UK, Japan, France, Germany, Italy, Spain and the US. - Assess the future prospects of the top 10 CRO companies with this report s analysis of each firm s strengths, weaknesses, opportunities and threats, in addition to an examination of growth strategies via acquisitions and divestments. - Measure the progress of other leading CRO companies by evaluating the financial performances of Aptuit, Life Sciences Research, Omnicare, SGS, CMIC, WuXi Pharmatech, Galapagos (Biofocus), LAB Research, United BioSource and Bio-Imaging.

2 Explore issues including... Industrial consolidation. Globalization and the need to provide a wider breadth of services to meet customer needs across the drug development process is driving consolidation. Budget pressures for biopharma. The economic slowdown has limited the availability of funds for risky businesses such as biotechnology. This has led to many projects being suspended. Consolidation in client industry. Consolidation in the pharma industry has led to the creation of larger entities with better bargaining power. This is beginning to impact upon contract payment terms. Demand for CRO services. Regulatory pressures are creating a need for larger trials and increasing development timelines. Regulatory delays and phase IV monitoring requirements are also fuelling demand for CRO services. Influx of private equity players. A number of factors are driving the participation of private equity players, including the nature of the service-based business model and recent shifts in the CRO industry led by globalization and the demand for full-service offerings. Discover... - Which countries are attracting offshore investment? - What are the trends in the global CRO industry? - Who are the top 20 players in the industry? - What is the market share of each of the global leaders by company? - What are the drivers and resistors of growth in the CRO industry? - How is consolidation expected to change the dynamics of the industry? - What are the key strategies of the leading CRO companies? - What are the strengths and weaknesses of the industry s top players? - Which phases of clinical research are driving the industry? Contents: The Top 10 Contract Research Organizations Executive summary 14 Industry overview 14 Quintiles 15 Covance 15 Pharmaceutical Product Development (PPD) 16 Charles River Laboratories (CRL) 16 ICON Clinical (ICON) 17 Parexel 17 MDS 18 Kendle 18 PharmaNet Development (PharmaNet) 19 PRA International 19 Chapter 1 Introduction 22 What is this report about? 22 Methodology 22 Chapter 2 Industry overview 24 Summary 24 Introduction 25 Market overview 25

3 Global CRO market: size and growth 25 Global positioning of the top 10 CROs 26 Key market drivers 29 Key market resistors 30 Business models 31 Full-services CROs 31 Niche CROs 31 Trends in the global CRO industry 32 Consolidation in the CRO industry 32 Evolution of software as a service (SaaS) based electronic data capture (EDC) 35 Implementation of biomarkers in clinical trials 36 Participation of private equity players 38 New CRO destinations 39 Asia-Pacific 39 India 39 China 40 Latin America 42 Eastern Europe 42 Africa 43 Chapter 3 Quintiles 46 Summary 46 Company overview 47 Recent financial performance 48 Growth strategies 48 Investing in infrastructure 48 Expansion of consulting business 50 Acquisitions and divestments 50 SWOT analysis 51 Strengths 52 Depth in service offerings 52 Strong presence in emerging economies 52 Weaknesses 53 Exposure in limited therapeutic areas 53 Opportunities 53 Launch of interactive data analysis tool 53 New facility in India 53 Expansion in Japan 53 Threats 54 Stringent regulations 54 Increasing competition 55 Chapter 4 Covance 58 Summary 58 Company overview 59 Recent financial performance 59 Performance by business segment 61 Growth strategies 61 Attaining operational efficiency through six sigma implementation 61 Develop capabilities in emerging markets 62 Acquisitions and divestments 62 SWOT analysis 63 Strengths 63 Global capabilities 63 Stronger therapeutic base 64 Strong liquidity position 64 Weaknesses 64 Declining performance in late-stage segment 64 Opportunities 65 Expanding facilities in mature pharmaceutical markets 65 R&D collaboration with Eli Lilly 65 Threats 66 Weakening early-stage development segment 66

4 Regulatory compliance 66 Chapter 5 Pharmaceutical Product Development 68 Summary 68 Company overview 69 Recent financial performance 69 Performance by business segment 70 Growth strategies 71 Collaboration for development of innovative compounds 71 Expansion in central laboratory services 71 Acquisitions and divestments 72 SWOT analysis 73 Strengths 74 Depth in phase II IV service offering 74 Strong financial performance 74 Weaknesses 74 Declining revenue contribution from PPD s discovery segment 74 Opportunities 75 Investment in technologies 75 Geographical expansion 75 Outsourcing deal with Merck 76 Threats 76 Dependence on a small number of industries and clients 76 Chapter 6 Charles River Laboratories 78 Summary 78 Company overview 79 Recent financial performance 79 Performance by business segment 80 Growth strategies 81 Building capabilities for clients 81 Acquisitions and divestments 81 SWOT analysis 82 Strengths 83 Strong technology platforms for pre-clinical testing 83 Weaknesses 83 Higher debt burden 83 Opportunities 84 Expansion in China 84 Threats 84 Cost cutting in biopharmaceutical industry 84 Chapter 7 ICON 86 Summary 86 Company overview 87 Recent financial performance 87 Performance by business segments 88 Growth strategies 88 Developing global capabilities and reach 88 Acquisitions and divestments 89 SWOT analysis 90 Strengths 90 Strong presence in oncology solutions 90 Technically enhanced service offerings 91 Unconventional service model 91 Weaknesses 92 Rising debt load 92 Opportunities 92 Expansion in India 92 Agreement with Phase Forward 92 Threats 93 Government regulations 93 Softness in non-critical Path studies 93

5 Chapter 8 Parexel 96 Summary 96 Company overview 97 Recent financial performance 97 Performance by business segments 98 Growth strategies 99 Expansion in emerging markets 99 Acquisitions and divestments 100 SWOT analysis 101 Strengths 101 Strong global presence 101 Stronger therapeutic presence 102 Weaknesses 102 Increased receivable turnover period 102 Opportunities 102 Expansion in early-phase service offerings 102 Threats 103 Consolidation in the industry 103 Declining R&D spending growth 103 Chapter 9 MDS 106 Summary 106 Company overview 107 Recent financial performance 107 Performance by business segment 109 Growth strategies 109 Internal restructuring 109 Investment in infrastructure across geographies 110 Acquisitions and divestments 110 SWOT analysis 111 Strengths 111 Robust performance of late-stage contract research services 111 Weaknesses 112 Limited therapeutic focus 112 Opportunities 112 Investment in technology 112 Expansion in Asian markets 113 Threats 113 Regulatory review 113 Chapter 10 Kendle 116 Summary 116 Company overview 117 Recent financial performance 117 Performance by business segment 119 Growth strategies 119 Participation in mega-trials 119 Acquisitions and divestments 120 SWOT analysis 121 Strengths 121 Strong presence in phase I IV clinical services 121 Growth in operating profit 122 Broader therapeutic exposure 122 Weaknesses 123 Rising debt burden 123 Opportunities 123 Growth in the early-stage research segment 123 Expansion in Asia-Pacific 124 Threats 124 Highly competitive environment 124 Chapter 11 PharmaNet 126

6 Summary 126 Company overview 127 Recent financial performance 127 Performance by business segments 129 Growth strategies 129 Global expansion of capacity 129 Early-stage expansion 129 Late-stage expansion 130 Investment in technology 130 Acquisitions and divestments 130 SWOT analysis 131 Strengths 131 Extensive services spectrum 131 Diverse client base across geographies 132 Weaknesses 133 Late-stage project cancellations 133 Opportunities 133 Investing in laboratory capabilities to analyze complex molecules 133 Threats 133 Legal proceedings 133 Refinancing convertible debt 134 Government regulations 134 Chapter 12 PRA International 136 Summary 136 Company overview 137 Recent financial performance 137 Growth strategies 138 Capacity expansion across geographies 138 Increased prominence in oncology 139 Acquisitions and divestments 139 SWOT analysis 140 Strengths 140 Services portfolio 140 Weaknesses 141 Limited therapeutic expertise 141 Lower sales growth during Opportunities 141 Collaboration with Frontage Laboratories 141 Growing opportunities in India 142 Threats 142 Intense competition 142 Regulatory compliance 143 Chapter 13 Other key players 146 Aptuit 146 Company overview 146 Recent financial performance 146 Life Sciences Research 147 Company overview 147 Recent financial performance 147 Omnicare 149 Company overview 149 Recent financial performance 149 SGS 151 Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to

7 Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

8 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Web Address: Office Code: The Top 10 Contract Research Organizations: Positioning, Performance and SWOT Analyses SC Product Formats Please select the product formats and quantity you require: Quantity Hard Copy: Electronic (PDF) - Single User: Electronic - Enterprisewide: USD USD 55 Shipping/Handling USD 3835 USD * Shipping/Handling is only charged once per order. * The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change. Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

9 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World